The Heart Rhythm Society issued a first-ever consensus statement on the evaluation, risk stratification and management of arrhythmogenic cardiomyopathy at its annual conference in San Francisco this spring.
A machine learning algorithm can now predict death and MI more accurately than certified cardiologists, according to research presented at the International Conference on Nuclear Cardiology and Cardiac CT in Lisbon, Portugal, this May.
A team funded by the National Institutes of Health has succeeded in growing human acellular vessels—implantable, bioengineered human blood vessels—to replace damaged vasculature in patients with end-stage kidney failure.
South Korean researchers are working on packing the ability to monitor heart health and detect signs of atrial fibrillation into what might be the smallest cardiology wearable to date: a “smart ring.”
The bioresorbable vascular scaffold, once an exciting prospect for cardiologists, saw a unique rise and fall in popularity within a year of its introduction to the CV market.
Ryan Madder, MD, is at the robotic controls for an experimental telestent procedure. In this case, the robotic controls are in a medical office building miles away from the cath lab and stent recipient. Source: Ryan Madder, MD.
Telehealth enthusiasts are optimistic about telestenting’s potential to solve access-to-care issues but concede that significant obstacles must be overcome before it will be ready for prime time.
The global market for transcatheter treatment of the mitral and aortic valves is expected to increase from $4 billion to $8 billion in the next five years, but barriers exist.
Atrial fibrillation patients with coronary artery disease pose a delicate balancing act for physicians. A growing awareness of bleeding vs. ischemic risks could soon lead to a steadier therapeutic response.
